GILD EBITDA Growth
Gilead Sciences · EBITDA Growth
GILD EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-87.84%period ending
GILD TTM EBITDA YoY % (-36.96% → -87.84%)
Year-over-year change
High-resolution chart · PNG
GILD ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -87.8418% | |
| 32.4608% | |
| 206.2458% | |
| 248.839% | |
| 108.2369% | |
| 121.1957% | |
| -57.7458% | |
| -63.3327% | |
| -50.4793% | |
| -54.0486% | |
| 18.5721% | |
| 40.6501% | |
| 23.3766% | |
| 16.376% | |
| -21.8642% | |
| -38.2446% | |
| -9.3165% | |
| 97.3092% | |
| 174.1108% | |
| 198.7376% | |
| 428.627% | |
| -36.9314% | |
| -45.3235% | |
| -38.4857% | |
| -83.4742% | |
| -32.1024% | |
| -26.6473% | |
| -41.7435% | |
| -12.6815% | |
| -26.681% | |
| -35.3229% | |
| -34.6561% | |
| -31.3037% | |
| -21.4138% | |
| -17.0977% | |
| -14.9708% | |
| -16.695% | |
| -19.4% | |
| -18.0252% | |
| -6.5431% | |
| 9.125% | |
| 21.8328% | |
| 43.6726% | |
| 70.3126% | |
| 90.5486% | |
| 166.2095% | |
| 235.7811% | |
| 174.8963% | |
| 126.9443% | |
| 55.6901% | |
| 14.319% | |
| 17.1332% | |
| 14.9501% | |
| 13.0411% | |
| 2.223% | |
| -1.7688% | |
| -1.6081% | |
| -1.3242% | |
| -3.0161% | |
| -8.9139% | |
| -7.5062% | |
| -2.9263% | |
| 13.302% | |
| 31.1842% | |
| 38.9599% | |
| 38.7129% | |
| 31.6439% | |
| 32.0735% | |
| 28.8875% | |
| 27.1422% | |
| 29.7439% | |
| 18.9544% | |
| 20.1292% | |
| 26.3344% | |
| 31.6896% | |
| 40.3549% | |
| 47.1047% | |
| 43.9272% | |
| 46.6903% | |
| 65.051% | |
| 63.0433% | |
| 76.8078% | |
| 74.8264% | |
| 63.3275% | |
| 73.4816% | |
| 66.5941% | |
| 87.0379% | |
| 97.1879% | |
| 98.1935% | |
| 178.308% | |
| 267.5622% | |
| 679.6774% | |
| 824.8689% | |
| 281.8506% | |
| 190.0347% | |
| 137.5345% | |
| 60.1972% | |
| -49.1833% | |
| -181.3857% | |
| -245.2101% |